e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Pulmonary circulation: animal models and experimental treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats
S. Guo, T. Wang, G. He, D. Xu, F. Wen (Chengdu, China)
Source:
Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Session:
Pulmonary circulation: animal models and experimental treatments
Session type:
Poster Discussion
Number:
484
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Guo, T. Wang, G. He, D. Xu, F. Wen (Chengdu, China). TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats. Eur Respir J 2013; 42: Suppl. 57, 484
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Contributions of TRPV4 to altered pulmonary vasoreactivity in mice with pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Pulmonary vasoreactivity in spontaneously hypertensive rats - Effects of leptin and endothelin-1
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Targeting aquaporin 1 reverses hypoxia-induced pulmonary hypertension in mice
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Peripheral arterial stiffness and endothelial dysfunction in pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load
Year: 2015
2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Renal denervation reduces pulmonary vascular remodeling in two experimental pulmonary arterial hypertension models
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
The effect of chronic dosing of riociguat on acute hypoxic pulmonary vasoconstriction in respiratory disease
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
Endothelium in pulmonary arterial hypertension
Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease
Year: 2007
Effect of roflumilast on hypoxia- and monocrotaline-induced pulmonary hypertension in rats
Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair
Year: 2007
Hypoxic pulmonary vasoconstriction in COPD-associated pulmonary hypertension: been there, done that?
Source: Eur Respir J, 50 (1) 1701191; 10.1183/13993003.01191-2017
Year: 2017
Apelin improves cardiac output in patients with pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
MIF/CD74 contributes to the endothelial pro-inflammatory phenotype in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
Source: Eur Respir J 2011; 37: 813-822
Year: 2011
Acute vasodilator response in different forms of pre-capillary pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept